ServiceUpdated on 14 July 2025
HOIST Corporation Ltd. open to joint research projects using patient-derived cells (PDC) and patient-derived xenografts (PDX)
About
HOIST Corp.’s core strength is our Patient Derived Cells (PDC)/Patient Derived Xenografts (PDX) technology. By using cancer cells taken directly from patients, our PDC/PDX models more accurately reflect the unique characteristics of cancer as it exists in the body. This makes our technology an invaluable tool for testing the efficacy of lead compounds before they move into human clinical studies.
HOIST Corp. is eager to explore joint research opportunities where our PDC/PDX technology can be used to test your lead compounds prior to clinical studies. Any inventions or discoveries derived from the use of these samples will belong to our collaboration partners, while HOIST Corp. retains the rights to cell and tissue culture methodologies.
We look forward to discussing potential collaboration opportunities with you at the networking event.